Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Conventional therapies and immunotherapies often fail to eradicate all cancer cells in advanced stages.
• Optimizing the integration of these treatments is crucial for synergistic effects and improved survival.
• The impact of conventional treatments on the immune system is not fully understood, posing challenges for combination strategies.

Purpose of the Study:

• To explore the immune mechanisms underlying conventional and targeted cancer therapies.
• To identify strategies for integrating conventional treatments with immunotherapy for enhanced anti-tumor effects.
• To elucidate how conventional therapies can prime the immune system to overcome resistance to immunotherapy.

Main Methods:

• Review of current understanding of cancer therapy resistance mechanisms.
• Analysis of how conventional treatments (chemotherapy, radiotherapy) influence immune responses.
• Investigation of damage-associated molecular patterns (DAMPs) and their role in immune cell priming.

Main Results:

• Conventional treatments can prime host T cells against tumor antigens, complementing direct cytotoxic effects.
• Cytotoxic therapies release DAMPs, stimulating innate cells to produce type I interferon and promote CD8+ T cell cross-priming.
• Specific chemotherapy and radiation protocols can increase tumor-infiltrating lymphocytes, enhancing immunotherapy efficacy.

Conclusions:

• A deeper understanding of the immunomodulatory effects of conventional therapies is essential.
• Novel combinatorial anticancer strategies integrating conventional treatments and immunotherapy can improve clinical outcomes.
• Harnessing the immune-priming effects of conventional therapies offers a promising avenue for overcoming cancer resistance.